Vesugen 20mg Peptide
For in-vitro laboratory research only. Not for human or animal administration.
Batch #: VPVS20100
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Batch-specific Certificates of Analysis available for all products.
Vesugen 20mg: overview
What the vial contains and what the material is, stated as specifications rather than as outcomes.
Vesugen supplied as a lyophilized powder in a sealed single-use vial containing 20 mg of material. Released to a specification of >99% purity by HPLC. Soluble in bacteriostatic water. Supplied for in-vitro laboratory research only. Not a drug, food or supplement. Not for human or veterinary use.
Volta does not provide dosing, administration or protocol guidance for any material listed.
Vesugen 20mg specifications
Every field the product record holds. A field with no value is omitted rather than printed as a dash.
- Fill
- 20mg
- Form
- Lyophilized powder
- Solubility
- Soluble in bacteriostatic water
- Shelf life
- 24 months from date of manufacture
Vesugen analytical verification and batch documentation
What the purity figure on this page is, who measured what, and which of the two a reader is looking at.
Specification. Every batch is released to >99% purity by HPLC. That is a threshold Volta sets, and it is a promise rather than a measurement.
Measurement. No certificate for this compound is published on the site yet. A batch-specific Certificate of Analysis is available on request, and the batch history lists the ones already published. Until one is published for this material, the figure above is the release specification and nothing on this page is a laboratory result.
Checking a certificate. The batch number printed beside the price is derived from the compound code and the vial strength; the lot number on a certificate is transcribed from the document. They are produced independently, so comparing them is a real check. How to read one is set out in the quality and testing methodology page.
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease.
Vesugen is the vascular representative of the Khavinson short peptide series, studied primarily in endothelial cell culture for effects on proliferation markers and on the expression of genes associated with vascular wall maintenance. Like the rest of the family it is proposed to act through direct interaction with DNA regulatory regions rather than through a membrane receptor, a mechanism that remains contested outside the originating research group. Supplied as a 20mg vial matching the presentation of the other bioregulator peptides in this catalogue.
- Released to a >99% purity specification by HPLC
- Lyophilized powder, 20mg per vial
- Soluble in bacteriostatic water
- For laboratory research use only
Frequently Bought Together
Vesugen 20mg
20mg
$59 USD
Bundle & Save
$94 USD
Save $4.70 USD
$140 USD
Save $14 USD
$209 USD
Save $31.35 USD
$283 USD
Save $56.60 USD
Click any product above to toggle selection
Related research materials
Vesugen 20mg: what is in the vial
The arithmetic specific to this 20mg vial, and what a milligram of Vesugen costs in each strength the catalogue carries. Concentrations are stated, not recommended.
Vial contents
20 mg
Lyophilised powder, reconstituted by the buyer
Cost of material
$2.95 / mg USD
CA$4.25 / mg in Canadian dollars
Concentration at each diluent volume
20 mg of dry material reaches these concentrations in the volumes below. A U-100 syringe marking is 0.01 ml by definition, so the last column is a unit conversion at each concentration rather than a quantity to use.
| Diluent added | Concentration | In 0.1 ml | Per U-100 unit |
|---|---|---|---|
| 1 ml | 20 mg/ml | 2 mg | 200 mcg |
| 2 ml | 10 mg/ml | 1 mg | 100 mcg |
| 3 ml | 6.67 mg/ml | 666.7 mcg | 66.7 mcg |
| 5 ml | 4 mg/ml | 400 mcg | 40 mcg |
For a volume this table does not list, the reconstitution calculator takes any vial size and diluent volume.
Vesugen purity and identity: how the figure is measured
What >99% (HPLC) means, the masses an identity check has to land on, and the entries that make a certificate of analysis checkable rather than decorative.
Stated purity
>99% (HPLC)
Area percent of the main peak by reversed-phase HPLC
Detection
214 nm
Why 214 nm
The sequence carries neither tryptophan nor tyrosine, so it has no absorbance at 280 nm. Detection is at 214 nm, on the peptide bond itself.
This matters when reading someone else's certificate: a purity figure quoted at 280 nm for a compound with no aromatic residue is measuring an absorbance the molecule does not have.
What a certificate for Vesugen should carry
A purity percentage on its own is not checkable. These are the entries that make one verifiable, and their absence is the most common weakness in a research-peptide certificate.
The chromatogram, not only the number
A stated area percent with no trace behind it cannot be read for the shape of the main peak or for what eluted beside it. The HPLC interpreter walks through what a trace shows.
Net peptide content, separately from gross mass
A lyophilised peptide is a salt, usually of trifluoroacetic or acetic acid, plus residual water. The vial's stated milligrams are gross; net peptide content is the fraction of that mass which is the molecule. The two differ by ten to twenty percent routinely, and only one of them is what the price is per milligram of. The net peptide content calculator converts between them.
The counterion, named
Which salt form the powder is in changes the net content and the pH the powder dissolves at. A certificate that never names it leaves both unknowable.
Water content, by a stated method
Loss on drying and Karl Fischer titration give different numbers, and a water figure with no method attached cannot be compared with anyone else's.
A laboratory and a report identifier
Without both, nothing on the document can be traced back to the laboratory that issued it. The red flag checker lists the rest.
Batch certificates are published as page images in the certificate library. The source PDFs are never served: a certificate is the most forgeable document a supplier publishes, and an editable copy carrying an accredited laboratory's letterhead is worth more to a counterfeiter than to a customer.
Vesugen storage and stability
Handling as the product record states it, followed by the degradation chemistry this particular sequence is and is not exposed to.
Handling
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
What holds up
The degradation routes this compound is not exposed to, which is as specific a fact as the ones it is.
No oxidation-labile side chain
no Met, Cys or Trp in the sequenceThe three residues that oxidise readily are all absent, so the most common degradation route for a research peptide does not apply to this one. Air in the vial headspace is not the risk here that it is for a methionine-containing compound.
No deamidation site
no Asn or Gln in the sequenceDeamidation is the slow clock on most reconstituted peptides, and it needs an asparagine or a glutamine to run. This sequence has neither, so time in solution does not convert it to a one-dalton-heavier, more acidic relative.
No ultraviolet chromophore
no Trp or Tyr in the sequencePhoto-oxidation of peptides runs mainly through the aromatic side chains, and this sequence has none. Storing in the dark remains good practice for the excipients and the diluent, but the molecule itself has no strong absorber for ultraviolet light to act on.
Net hydrophilic
GRAVY -3.63A negative grand average of hydropathy means the side chains are on balance polar, which is the profile that stays in solution rather than associating. Freeze-thaw cycles are still worth avoiding, but this compound is not one of the hydrophobic sequences that aggregate irreversibly at an ice front.
Solubility window
calculated pI 4, net charge -1 at pH 7A peptide is least soluble within about a pH unit of its isoelectric point, where it carries no net charge. This one is far enough from neutral that it holds a real charge in an ordinary diluent, which is what keeps it dissolved.
Derived from the primary sequence KED, calculated isoelectric point 3.97, GRAVY -3.633. Check the arithmetic with the peptide property calculator and the freeze-thaw estimator.
Vesugen compared with Cardiogen and BPC-157
Pharmacological class, half-life, evidence grade, competition status and cost per milligram, side by side.
| Compound | Class | Half-life | Evidence | WADA | Cheapest per mg |
|---|---|---|---|---|---|
| Vesugenthis page | Cardiovascular / Bioregulator | Not established in humans | DLimited Evidence | Not listed | $2.9520mg vial, out of stock |
| Cardiogen | Cardiovascular / Anti-Aging | ~20-40 minutes | DAnimal/Preclinical Only | Not listed | $3.4520mg vial, out of stock |
| BPC-157 | Healing & Recovery | ~15 min IV (animal data); oral activity persists 24+ hours | CPhase I–II Clinical Trials | Prohibited | $4.6010mg vial |
| SS-31 | Metabolic / Mitochondrial | ~4 hours | AFDA Approved | Not listed | $4.9010mg vial |
| TB-500 | Healing & Recovery | <2 hours plasma half-life; tissue effects persist 2–3 days | DPreclinical | Prohibited | $6.9010mg vial |
Evidence grades and half-lives are as recorded in the compound database, which cites its own sources on each compound page. Per-milligram prices are the cheapest strength each compound is currently listed at, in US dollars, and an out-of-stock note means that figure is not purchasable today. Cross-trial comparisons of efficacy are not comparisons: no head-to-head trial exists for most of these pairs.
Vesugen in Canada
Price in Canadian dollars, where the parcel ships from, and how long it takes.
Price in CAD
CA$85
The figure charged, not a converted estimate
Ships from
British Columbia
A domestic parcel, so no import clearance step
Transit
2 to 5 business days
After 1 to 2 business days of handling
Free standard shipping
Over CA$250
A bar set for this market, not converted from the US one
Vesugen 20mg ships from British Columbia to Canadian addresses, so the parcel never crosses a border. That removes the failure a Canadian buyer of research peptides is usually weighing: an inbound international shipment can be held for import clearance or seized, and a domestic one has no clearance step to be held at.
Shipping is quoted live against the delivery address at checkout rather than estimated here, and both the standard and express tiers show their price and transit window before a payment method is chosen. The figure the page shows is the figure the rail charges: all three settlement rails price shipping through the same functions the quote does.
The Canadian figure above is not a loose conversion. Each product's US dollar base is chosen so that the live conversion lands on the Canadian shelf price set for this market, and the result is pushed up to a whole dollar rather than left carrying cents, so one figure serves the page, the feed and every payment rail. See the shipping policy for carriers and cut-off times, and the legal position on research peptides in Canada for the regulatory picture.
Vesugen Mechanism of Action
Vesugen is the tripeptide Lys-Glu-Asp, KED. It belongs to the Khavinson family of ultrashort peptide bioregulators but sits slightly apart from cardiogen and cortagen: it is three residues rather than four, and it does not share their Ala-Glu-Asp core. It begins with lysine, which is the residue that also begins KE, the dipeptide known as vilon and the most studied member of the whole family.
The proposed mechanism is the family's. These peptides are held to be carried into cells by peptide transporters rather than crossing membranes passively, to reach the nucleus, and to interact directly with DNA and histone proteins so as to alter transcription of particular genes. Work on transport using POT family and L-type amino acid transporters is the most concrete and testable part of that account, and it applies to the family as a class.
Vesugen is assigned to vascular endothelium under the same sequence-complementarity hypothesis that assigns AEDR to cardiac tissue and AEDP to neural tissue. Because it is a tripeptide rather than a tetrapeptide, its relationship to the family's structural logic is looser: the hypothesis is framed around which residue differs at a fixed position, and a peptide of different length does not fit that comparison cleanly.
Transporter-mediated uptake
Reported carriage into cells by POT family peptide transporters and L-type amino acid transporters rather than by passive diffusion, which is the best-supported element of the family's mechanism.
Nuclear entry
The peptide is proposed to reach the nucleus, a prerequisite for any direct effect on transcription.
DNA and histone interaction
Proposed direct engagement with DNA and histone proteins, altering chromatin accessibility and gene expression.
Assigned vascular target
Vesugen is assigned to vascular endothelium on the family's sequence-specificity hypothesis rather than on a direct demonstration of endothelial selectivity.
Altered gene expression
Changes in expression of signalling molecules and of genes associated with tissue function are the measured endpoints across this literature.
Vesugen and Khavinson Peptide Research Findings
Published work addresses the peptide family, and predominantly the lysine-containing dipeptide KE, rather than KED specifically. Each entry names the peptide studied.
Regulation of SIRT1 and PARP gene expression by a lysine-containing family member
The KE peptide was reported to regulate SIRT1, PARP1 and PARP2 gene expression and protein synthesis in human mesenchymal cells. This is the family's clearest transcriptional result and it concerns the member structurally closest to KED.
In vitroTransport of ultrashort peptides characterised
A study of transport through POT and LAT carriers addressed how these peptides enter cells at all, which is the necessary first step for any intracellular mechanism and applies across the family.
In vitroDirect comparison of two family members on one cell type
A comparison of KE and AED peptides on human skin fibroblast function is one of the few studies designed to distinguish members from each other rather than treating the family as interchangeable.
In vitroThe KE sequence located within the human proteome
Work identifying the KE peptide in the human proteome addressed whether these sequences occur naturally rather than existing only as synthetic constructs, which bears directly on whether an endogenous regulatory role is plausible.
In vitroShort peptides and skin function during ageing
A review of short peptides in the regulation of skin function during ageing collected the family's dermatological work, a tissue where the vascular component of the reported effects is relevant.
ObservationalEffects on interleukin-2 gene expression in splenocytes
Short peptides were reported to affect interleukin-2 gene expression in splenocytes in vitro, extending the transcriptional claims to immune cells and providing an early example of the family's proposed mode of action.
In vitroVesugen Molecular Information
| Sequence | Lys-Glu-Asp |
| Single-letter Code | KED |
| Length | 3 amino acids |
| Molecular Formula | C15H26N4O8 |
| Molecular Weight | 390.4 g/mol, computed from the sequence |
| Family | Khavinson ultrashort peptide bioregulators |
| Relationship to Other Members | A tripeptide, unlike the AED-core tetrapeptides cardiogen and cortagen. Shares its N-terminal lysine with KE, the dipeptide vilon |
| Assigned Tissue | Vascular endothelium, on the sequence-specificity hypothesis rather than direct demonstration |
| Proposed Uptake | POT family peptide transporters and L-type amino acid transporters |
| Appearance | White lyophilised powder |
A Tripeptide in a Family Built Around Tetrapeptides
The Khavinson family's organising idea is that a shared core with one differing residue directs each peptide to a different tissue. Cardiogen is AEDR, cortagen AEDP, epithalon AEDG: same three residues, different fourth.
Vesugen does not fit that pattern. It is three residues, KED, and shares no core with those three. Its structural relative within the family is KE, the dipeptide vilon, with which it shares an N-terminal lysine and which is by some margin the most studied member of the group.
This is worth noticing because the specificity hypothesis is stated in terms of a fixed comparison that a differently sized peptide cannot enter. Whatever directs KED to vascular endothelium, if anything does, it is not the fourth-residue argument that carries the tetrapeptides, and the literature does not offer a separate account for it.
Almost All the Evidence Concerns Other Members
Searching for KED specifically returns very little. The family literature is substantial but dominated by KE and by AEDG, epithalon. That pattern holds across every compound in this group and it is the single most important thing to understand before reading a product description for any of them.
Under the family's own premise the peptides are not interchangeable, since the whole point is that different sequences engage different genes. Evidence obtained with KE is therefore not evidence about KED, and presenting it as such is inconsistent with the reason for selling them as separate products.
The sources below name which peptide each study used. The closest relative to KED among well-studied members is KE, which is why that work is included, but the relationship is structural rather than evidential.
What the Vascular Assignment Rests On
Vesugen is described as targeting vascular endothelium. In the indexed literature there is no controlled demonstration of endothelial selectivity for KED, and the assignment appears to follow from the family's general framework rather than from a study designed to establish it.
That does not make the assignment wrong. It makes it unverified, which is a different and more accurate description than either endorsing it or dismissing it.
There is no approved product containing KED in any Western jurisdiction and no controlled human efficacy trial. Material supplied for research is for in-vitro laboratory use only, and nothing here is guidance for use in humans or animals.
Handling and Analytical Considerations
At 390 daltons across three residues this is the smallest peptide in the catalogue, and it is highly charged: a lysine side-chain amine against glutamate and aspartate carboxylates, plus free terminal groups. That combination gives it minimal retention on a standard reversed-phase column.
In practice a method developed for larger peptides will elute it at or near the void volume, where it cannot be separated from salts and small polar impurities. Ion-pairing or a dedicated polar-retention method is the appropriate approach, and a purity figure produced without one is reporting less than it appears to.
Vesugen Research FAQ
Vesugen in Summary
Vesugen is the tripeptide KED from the Khavinson ultrashort peptide family, proposed to enter cells through peptide transporters and alter transcription by direct interaction with DNA. Unlike cardiogen and cortagen it is three residues and shares none of their AED core.
Its assignment to vascular endothelium follows from the family's general framework rather than from a study establishing it, and almost all published evidence concerns other members. Its size and charge also make it the hardest peptide here to retain chromatographically.
Scientific References
Primary literature and public trial registries only. No supplier or retailer pages are cited.
- 1KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal cellsKhavinson VK, Linkova NS, et al. · Advances in Gerontology · 2023
- 2Transport of Biologically Active Ultrashort Peptides Using POT and LAT CarriersKhavinson V, Linkova N, Dyatlova A, et al. · International Journal of Molecular Sciences · 2022
- 3Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin FibroblastsFridman NV, Linkova NS, et al. · Bulletin of Experimental Biology and Medicine · 2020
- 4Peptide KE in Human ProteomeTerekhov AY, Kormilets DY, et al. · Bulletin of Experimental Biology and Medicine · 2020
- 5Short peptides: regulation of skin function during agingKhavinson VKh, Linkova NS, et al. · Advances in Gerontology · 2020
- 6In vitro effect of short peptides on expression of interleukin-2 gene in splenocytesKazakova TB, Barabanova SV, et al. · Bulletin of Experimental Biology and Medicine · 2002
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Vesugen 20mg: frequently asked questions
Answered from the product record and the certificate file. Volta does not answer questions about administration, dosing or protocols.
What is supplied in a 20 mg vial of Vesugen?
A sealed single-use vial containing 20 mg of Vesugen as a lyophilized powder. Soluble in bacteriostatic water. No diluent, syringe or other supply is included.
Is Vesugen supplied for human use?
No. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
What purity is this Vesugen released to?
>99% by HPLC. That figure is a release specification, a threshold Volta sets for every batch, and it is not the same kind of statement as a purity measured by a named laboratory for a named lot.
Is there a certificate of analysis for this Vesugen vial?
A batch-specific Certificate of Analysis is available for this product on request. It is not published on the site yet: the batch history on the quality page lists the certificates already published, and this vial is covered by the release specification until its own is added there.
How should Vesugen be stored before reconstitution?
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
Where does this ship from?
British Columbia, Canada. Canadian orders are domestic, so they clear no customs and pay no import duty. International orders ship from the same facility.
Explore Research
Peptide Tools
More from the research catalogue
Every compound below has its own specification, batch number and certificate page, whether or not a vial is in stock today. Supplied for laboratory research use only.